Eden Biologics’ Leading Biosimilar Program Receives Phase 3 Approval in Europe
Hsinchu, Taiwan, 31 August 2021
We’ve once again achieved a huge corporate milestone and are excited to share the great news with all of you! Our EB-CLIN-1001-03 Phase 3 Clinical Trial for our leading Biosimilar Program EB1001, received approval from Hungary’s National Institute of Pharmacy and Nutrition (OGYÉI), as well as the Ethics Committee! Meanwhile, we are awaiting feedback/news from Poland and other Countries we have submitted in. We’re truly appreciative of the entire team effort that made this Phase 3 possible. Congratulations to the entire Eden family!
About Eden Biologics, Inc.
Eden Biologics is a biopharmaceutical company established in 2012 and after a transformation under new executive leadership led by James Huang, Chairman and CEO (also Managing Director of KPCB China), Eden continues to focus on three biotech sectors: 1) Accelerating the development programs for clients through the provision of Contract Development and Manufacturing Services (from cell line development to commercial manufacturing with regulatory filing support; 2) Developing a Proprietary Biosimilar Pipeline; and 3) Collaborating & Licensing of New and Innovative Biologics.
For more information, please contact us at partner@edenbiologics.com